Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT

NCT06904183 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

320

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma Non-resectable

Interventions

COMBINATION_PRODUCT: LEN+SIN+DEB-TACE+HAIC
COMBINATION_PRODUCT: LEN+SIN+DEB-TACE

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]